Announced
Synopsis
Boston Scientific, a biomedical/biotechnology engineering firm, agreed to acquire Axonics, a medical technology company, for $3.4bn. "We are excited to add Axonics technologies to the Boston Scientific portfolio, a combination that we expect will further strengthen our ability to serve urologists who are treating patients living with these often-chronic conditions," Meghan Scanlon, Boston Scientific Senior Vice President and President, Urology. On March 22, 2024, Axonics stockholders approve the acquisition agreement with Boston Scientific.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.